Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. - Wikidata - wikimedia - TriplyDB

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.

http://www.wikidata.org/entity/Q37585487

about

The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Decitabine reactivated pathways in platinum resistant ovarian cancer.Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer Past, present and future targets for immunotherapy in ovarian cancer Immunotherapy for ovarian cancer.Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients.HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer.Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells.Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy.PRAME expression and promoter hypomethylation in epithelial ovarian cancer.LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients.Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review Potential approaches for more successful dendritic cell-based immunotherapy.Decitabine: a promising epi-immunotherapeutic agent in solid tumors.Immunotherapy in Gynecologic Cancers: Are We There Yet?Improving cancer immunotherapy with DNA methyltransferase inhibitors.Marked for death: targeting epigenetic changes in cancer.Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy Epigenetics: A primer for clinicians.Factors affecting the persistence of drug-induced reprogramming of the cancer methylome.Combining Epigenetic and Immunotherapy to Combat Cancer.Emerging biological therapies for the treatment of myelodysplastic syndromes.Rewiring the solid tumor epigenome for cancer therapy.Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.DNA Hypomethylating Drugs in Cancer Therapy.A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.Therapeutic Cancer Vaccines.Optimization of norovirus virus-like particle production in Pichia pastoris using a real-time near-infrared bioprocess monitor.DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer.The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.Adaptive Resistance to Cancer Immunotherapy.NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-Lymphocyte Responses in Patients with Myelodysplastic Syndrome.Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.Mechanisms regulating T-cell infiltration and activity in solid tumors.NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.

P2860

Q33660069-523C507A-4AD4-47A4-82F2-8A8A9CA3930B Q33976957-14861431-8327-4461-95CC-09F849757083 Q34015590-2B0C9C9E-B02A-455A-9144-EDDBE8BB915D Q35034010-71EBBFCF-24EF-4D61-8DE5-DB26F58BEEEB Q35164189-8A57B8AF-7F80-4208-8B00-3729376C74FC Q35944106-34BF0133-1B0F-4A3C-A9C4-CDA6EEE6354C Q35996647-592578BA-A955-4935-A72A-F9F89F99747D Q36015063-F28C2006-4D69-48BA-BE05-CF88C812F398 Q36213219-A695A5C3-E6DC-4ACB-922D-5AD1641FA0DF Q36214731-7104AB1B-C30E-4DE3-9342-FBDA7AA17A38 Q36407481-19ACA220-B94A-4768-B421-9E7D893F2410 Q37022306-5552D0F4-C986-4D38-8C9F-B15F730DD5F9 Q37079110-EC1F3B94-7473-4731-8C59-478B5C1CF34F Q37564420-E06A58C3-094C-4F9A-AC99-884EFD620C4C Q37622031-FDA6BFD1-D09E-4CEB-B380-87E6AAB1B27F Q37724905-1DFA1F7C-B78E-4215-A56F-C37439A0F32C Q38305650-2F07D0BD-4C2C-4ED2-9A3A-EE60EC7D38BA Q38314204-0CD2011A-5F26-4005-AC49-AF89CE4EDB6F Q38608730-59EE9668-D5A5-4B24-BC3E-14545010FE4B Q38662760-C82A3583-F99E-482F-8133-AB1579F9BD5E Q38747872-14BFAC31-CA88-49EB-BAE5-EA673A11BD67 Q38749824-A62983D2-250B-4A62-A738-7B6A03977C55 Q38770916-6556F16D-0B6D-47D6-AD2E-4C5DADD65CED Q38777889-6B6A519D-E21F-4A39-906E-B626E449D613 Q38779204-6800188B-03E0-4F52-8D0F-38FB4E72BBF6 Q38834981-535D0D0B-314B-49C2-8B9F-EB33B5B21039 Q38895216-9211CDE6-8B66-4C56-81A9-F65846703F47 Q38952962-7AD96EF5-100C-49B0-A42A-CF6D13F3F950 Q38979940-74F9E5C2-64EC-4468-8B43-88A5AFE91C8E Q38992236-7F064657-C7C2-4149-A58E-993D64BA2F88 Q40728648-E66FE4D1-1B58-44A5-BEF4-C1F4DF96260E Q40988893-994AB152-7BBA-4365-890D-6BC6ED0C44A7 Q41247038-2D17F73C-2264-4857-91FD-960FE9C379C6 Q46166592-D9382BEF-23EF-4877-A237-6D8E172DA195 Q47244891-DF85C680-C71E-40AD-88EB-961843EC48AD Q47252744-771416F3-0727-4C25-9FB2-EFABBBD05BAE Q47923445-660AB9E2-125C-455C-84D6-5E03A11C6251 Q49921990-8E4A77BA-4407-4F76-95FF-7A2339C62044 Q50089395-C0B0AE84-6A1B-4BB5-9AF7-1BCE2CD07704 Q51065844-375455C0-AE2A-41F8-A148-B0149583A3BA

P2860

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.

http://www.wikidata.org/entity/Q37585487

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.

@en

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.

@nl

type

label

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.

@en

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.

@nl

prefLabel

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.

@en

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.

@nl

P1433

Q37585487-972DE93C-0ACE-41B2-AF29-5EAC6858C6DF

P1476

Q37585487-C07BB458-42C8-4D28-B05F-096EA5E39C53

P2093

Q37585487-04C23AD5-1AC2-4382-A935-759B46F6107C

Q37585487-21F13A12-AC6E-4468-BCCF-3205303C14D9

Q37585487-4B7C957D-F0F7-468C-A1BD-9C5AD1DD97E0

Q37585487-526D751A-5C88-4D8C-BE67-35E4CBF088AF

Q37585487-5873CB32-C71A-4DFA-BFFE-602B47C1AE9A

Q37585487-5A970B4B-9957-4DC5-BD57-4A0B72A244D8

Q37585487-6298601E-AD87-477E-9868-65CB43D84D75

Q37585487-6ED2E710-F8DE-4293-93CB-CCE6D1B340C6

Q37585487-758AD7FF-66F9-4E52-82FB-AFFBA9645761

Q37585487-A00374FA-DECB-4E3B-8A1B-D9DC701E38BF

P2860

Q37585487-008F69C3-130C-4D7B-BFD6-E1B0BF932E43

Q37585487-1045E874-B7AF-4926-A476-32A6B937499A

Q37585487-11838AB1-3C60-479E-9E87-74222F00BEA4

Q37585487-190E56E2-A4EA-4B0C-9A28-20B74AA3C32E

Q37585487-1C17C01B-48E0-484C-93D6-82420D4472BE

Q37585487-1C2BF634-7282-401A-BD28-5A217BB8C416

Q37585487-29427B76-0FAA-492C-A539-013C3C0F03D0

Q37585487-2E54A75A-19BD-4746-9EE1-483377EE0A9B

Q37585487-2F645328-F81E-47D3-A41D-8E3B3D3E4391

Q37585487-40749796-D20E-449F-8DFD-A0D49C0969C9

P304

Q37585487-9E2016E6-7CA1-48A8-B64F-57810383BB46

P31

Q37585487-09FEFC63-67AE-425E-AFA1-89F527C99709

P356

Q37585487-A219050B-BB3C-4625-8E51-F82290E566FD

P433

Q37585487-8B783D3E-15B4-47AA-8EAA-6E753A0E2673

P478

Q37585487-2D5C259C-9027-4BE0-A003-34BD10DCE671

P50

Q37585487-81B7E6F5-27A9-4B62-92E6-49BAD07CA301

P577

Q37585487-F0DBF6DB-4B61-4FDA-A1F5-9EA1BE355867

P5875

Q37585487-AC37606A-481C-44F4-BDFC-CCBA01D993B0

P698

Q37585487-6F1BCCB6-EEE8-4FDA-AFEC-512CE84A8DB1

P921

Q37585487-53E18273-4E33-469C-B895-DD27F33DC95B

P932

Q37585487-45DB00A8-A05F-495B-8318-47BE6ECB212E

P356

2326-6066.CIR-13-0126

P1433

Cancer immunology research

P1476

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.

@en

P2093

Adam R Karpf

http://www.w3.org/2001/XMLSchema#string

Amy Beck

http://www.w3.org/2001/XMLSchema#string

Anthony Miliotto

http://www.w3.org/2001/XMLSchema#string

Austin Miller

http://www.w3.org/2001/XMLSchema#string

Carl A Batt

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Griffiths

http://www.w3.org/2001/XMLSchema#string

Gerd Ritter

http://www.w3.org/2001/XMLSchema#string

Junko Matsuzaki

http://www.w3.org/2001/XMLSchema#string

Paulette Mhawech-Fauceglia

http://www.w3.org/2001/XMLSchema#string

Sacha Gnjatic

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter

DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

The immunobiology of cancer immunosurveillance and immunoediting

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.

Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.

Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation.

Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer

P304

37-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-13-0126

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260242470

http://www.w3.org/2001/XMLSchema#string

P698

24535937

http://www.w3.org/2001/XMLSchema#string

P921

P932

3925074

http://www.w3.org/2001/XMLSchema#string